JP2021513848A - Ｌａｇ３に結合する治療用分子 - Google Patents

Ｌａｇ３に結合する治療用分子 Download PDF

Info

Publication number
JP2021513848A
JP2021513848A JP2020543560A JP2020543560A JP2021513848A JP 2021513848 A JP2021513848 A JP 2021513848A JP 2020543560 A JP2020543560 A JP 2020543560A JP 2020543560 A JP2020543560 A JP 2020543560A JP 2021513848 A JP2021513848 A JP 2021513848A
Authority
JP
Japan
Prior art keywords
single domain
lag
domain antibody
binding
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020543560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513848A5 (enExample
Inventor
キャロリン、エドワーズ
アンジェリカ、セッテ
イザベル、オスフ
ユミン、テン
ジェームズ、レッグ
ダビド、エスソロス、ムルガレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crescendo Biologics Ltd
Original Assignee
Crescendo Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crescendo Biologics Ltd filed Critical Crescendo Biologics Ltd
Publication of JP2021513848A publication Critical patent/JP2021513848A/ja
Publication of JP2021513848A5 publication Critical patent/JP2021513848A5/ja
Priority to JP2024116130A priority Critical patent/JP2024156719A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
JP2020543560A 2018-02-16 2019-02-18 Ｌａｇ３に結合する治療用分子 Pending JP2021513848A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024116130A JP2024156719A (ja) 2018-02-16 2024-07-19 Ｌａｇ３に結合する治療用分子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1802573.4 2018-02-16
GBGB1802573.4A GB201802573D0 (en) 2018-02-16 2018-02-16 Therapeutic molecules that bind to LAG3
PCT/GB2019/050425 WO2019158942A1 (en) 2018-02-16 2019-02-18 Therapeutic molecules that bind to lag3 and pd1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024116130A Division JP2024156719A (ja) 2018-02-16 2024-07-19 Ｌａｇ３に結合する治療用分子

Publications (2)

Publication Number Publication Date
JP2021513848A true JP2021513848A (ja) 2021-06-03
JP2021513848A5 JP2021513848A5 (enExample) 2022-02-24

Family

ID=61783706

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543560A Pending JP2021513848A (ja) 2018-02-16 2019-02-18 Ｌａｇ３に結合する治療用分子
JP2024116130A Pending JP2024156719A (ja) 2018-02-16 2024-07-19 Ｌａｇ３に結合する治療用分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024116130A Pending JP2024156719A (ja) 2018-02-16 2024-07-19 Ｌａｇ３に結合する治療用分子

Country Status (11)

Country Link
US (2) US11951172B2 (enExample)
EP (1) EP3752188A1 (enExample)
JP (2) JP2021513848A (enExample)
KR (1) KR20200123164A (enExample)
CN (1) CN111727057A (enExample)
AU (1) AU2019220621A1 (enExample)
CA (1) CA3089419A1 (enExample)
GB (1) GB201802573D0 (enExample)
IL (2) IL299443B2 (enExample)
SG (1) SG11202006696UA (enExample)
WO (1) WO2019158942A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565842A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
CA3082297A1 (en) 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
WO2020125763A1 (en) * 2018-12-20 2020-06-25 Biocytogen Jiangsu Co., Ltd. Genetically modified non-human animal with human or chimeric lag3
US12653809B2 (en) 2019-07-30 2026-06-16 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition
WO2021247789A1 (en) * 2020-06-04 2021-12-09 Leidos, Inc. Immunomodulatory compounds
WO2022109987A1 (en) * 2020-11-27 2022-06-02 Shanghai Benemae Pharmaceutical Corporation Novel anti-lag3 antibodies and methods of making and using the same
JP7847451B2 (ja) * 2021-03-02 2026-04-17 花王株式会社 アトピー性皮膚炎による皮膚痒みの症度悪化の検出方法
EP4313311A1 (en) * 2021-03-31 2024-02-07 Merus N.V. Multispecific binding moieties comprising novel pd-1 binding domains
WO2024036194A1 (en) * 2022-08-09 2024-02-15 Proteintech Group, Inc. Multivalent linkers used for antibody labeling
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof
WO2024196072A1 (ko) * 2023-03-20 2024-09-26 경북대학교 산학협력단 Lag-3에 결합하는 펩타이드 및 이의 용도
KR20250088543A (ko) * 2023-05-19 2025-06-17 서울대학교산학협력단 Cd3 유전자 편집된 cd3 표적 스위처블 car-t 세포
CN120118187B (zh) * 2025-03-19 2025-09-19 珠海市人民医院 一种抗lag3抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087589A2 (en) * 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
JP2017532059A (ja) * 2014-08-19 2017-11-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｌａｇ３抗体および抗原結合性フラグメント

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
ES2386366T3 (es) 2005-02-18 2012-08-17 Medarex, Inc. Anticuerpo monoclonal humano contra el antígeno de membrana específico de la próstata (PSMA)
EP1919504B1 (en) 2005-08-03 2013-10-16 iBio, Inc. Antibody to bacillus anthracis protective antigen
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP2011514385A (ja) 2008-03-17 2011-05-06 アラーガン、インコーポレイテッド 炎症を処置するためのｓ１ｐ３受容体阻害剤
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US20130266567A1 (en) 2010-12-01 2013-10-10 Haren Arulanantham Anti-serum albumin binding single variable domains
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
WO2013167883A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
CN103087171B (zh) 2012-12-24 2015-01-14 中国人民解放军第四军医大学 一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
CN103333249A (zh) 2013-06-14 2013-10-02 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用
MX2016002544A (es) 2013-09-04 2016-06-17 Squibb Bristol Myers Co Compuestos utiles como inmunomoduladores.
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
KR20150089702A (ko) 2014-01-28 2015-08-05 제일모직주식회사 신규 화합물, 신규 폴리머, 이를 포함하는 착색제, 이를 포함하는 감광성 수지 조성물 및 컬러필터
WO2015116539A1 (en) 2014-01-28 2015-08-06 Bristol-Myers Squibb Company Anti-lag-3 antibodies to treat hematological malignancies
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
CN106459204B (zh) 2014-04-25 2021-02-02 皮埃尔法布雷医药公司 Igf-1r抗体及其作为定位载体用于治疗癌症的用途
TWI693232B (zh) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
PT3177644T (pt) 2014-08-05 2021-01-13 MabQuest SA Reagentes imunológicos que se ligam a pd-1
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
PL3209698T5 (pl) 2014-10-22 2022-04-25 Crescendo Biologics Limited Mysz transgeniczna
WO2016073760A1 (en) 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
CA2971734C (en) 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
DK3298030T5 (en) 2015-05-18 2024-10-07 Pieris Pharmaceuticals Gmbh Anti-cancerfusionspolypeptid
CN105061597B (zh) 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
PE20231958A1 (es) * 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
CN106397592A (zh) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
PE20181349A1 (es) 2015-10-07 2018-08-22 Hoffmann La Roche Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
IL304871A (en) 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
JP2019506155A (ja) 2016-01-12 2019-03-07 クレッシェンド、バイオロジックス、リミテッドＣｒｅｓｃｅｎｄｏ Ｂｉｏｌｏｇｉｃｓ Ｌｉｍｉｔｅｄ 治療分子
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
KR20190014525A (ko) 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP3565842A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
WO2018148223A1 (en) 2017-02-09 2018-08-16 Memorial Sloan Kettering Cancer Center Anti-kir3dl1 antibodies
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
EP3425763B1 (en) * 2017-07-03 2020-11-18 France Brevets Coupling interface and method of operation
KR20200037250A (ko) * 2017-07-06 2020-04-08 메뤼스 엔.페. 세포에 의해 발현되는 생물학적 활성을 조절하는 항체
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
CA3082297A1 (en) 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
GB201818460D0 (en) 2018-11-13 2018-12-26 Crescendo Biologics Ltd Single domain antibodies that bind human serum albumin
US20220220215A1 (en) 2019-05-15 2022-07-14 Crescendo Biologics Limited Binding molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017532059A (ja) * 2014-08-19 2017-11-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｌａｇ３抗体および抗原結合性フラグメント
WO2017087589A2 (en) * 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EMBO MOLECULAR MEDICINE, vol. 3, JPN6023029516, 2011, pages 581 - 592, ISSN: 0005511759 *
FEBS LETTERS, vol. 592, JPN6023029515, 2018, pages 621 - 630, ISSN: 0005511760 *
FRONTIERS IN IMMUNOLOGY, vol. Vol.8, Article 42, JPN6023029514, 2017, pages 1 - 12, ISSN: 0005511761 *

Also Published As

Publication number Publication date
IL299443A (en) 2023-02-01
JP2024156719A (ja) 2024-11-06
US20240350651A1 (en) 2024-10-24
CA3089419A1 (en) 2019-08-22
IL299443B1 (en) 2023-09-01
US20210015937A1 (en) 2021-01-21
SG11202006696UA (en) 2020-08-28
KR20200123164A (ko) 2020-10-28
EP3752188A1 (en) 2020-12-23
IL276063A (en) 2020-08-31
IL276063B2 (en) 2023-06-01
WO2019158942A1 (en) 2019-08-22
IL299443B2 (en) 2024-01-01
GB201802573D0 (en) 2018-04-04
CN111727057A (zh) 2020-09-29
AU2019220621A1 (en) 2020-09-24
US11951172B2 (en) 2024-04-09

Similar Documents

Publication Publication Date Title
JP7525567B2 (ja) プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
US20240350651A1 (en) Therapeutic molecules that bind to lag3 and pd1
JP7271637B2 (ja) 抗ｐｓｍａ抗体、ｐｓｍａ及びｃｄ３と結合する二重特異性抗原結合分子、ならびにその使用
TWI830761B (zh) 針對cldn18.2和cd3之抗體構建體
US20260078166A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
JP7312168B2 (ja) Ｃｄ１３７に結合するシングルドメイン抗体
TWI875679B (zh) 藉由細胞表現之調控生物活性的抗體
US11505599B2 (en) T cell receptor-like antibodies specific for Foxp3-derived peptides
JP2023549116A (ja) 選択性が増大した多標的二重特異性抗原結合分子
US20220220215A1 (en) Binding molecules
WO2023011431A1 (zh) 一种cd16抗体及其应用
JP2026508096A (ja) 治療抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240722

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008